According to DeepLearning.AI, Johnson & Johnson has refined its generative AI strategy after 900 internal experiments, applying this technology to accelerate drug development and predict supply chain disruptions. These advancements are likely to enhance operational efficiency in the pharmaceutical sector, which may influence pharma-related crypto assets and tokenized supply chain solutions by demonstrating real-world enterprise AI adoption (source: DeepLearning.AI, May 13, 2025).